A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

November 22, 2025

Study Completion Date

December 1, 2025

Conditions

Hepatic ImpairmentHealthy Participants

Interventions

DRUG

Opevesostat

Oral film-coated tablet

DRUG

Prednisone

Oral tablet

DRUG

Fludrocortisone acetate

Oral tablet

Trial Locations (2)

RECRUITING

Clinical Pharmacology of Miami ( Site 0002), Miami

RECRUITING

Texas Liver Institute ( Site 0001), San Antonio

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY